Elixinol Wellness Ltd · ASX:EXL
Elixinol Wellness — Elixinol Global — 31st Annual ROTH Capital Partners Conference 2019
31 slides from Elixinol Wellness's conference presentation, Mar 19, 2019
Slide 1: ASX Announcement: Elixinol Global to Present at U.S. Investor Conferences
ASX Announcement 13 March 2019 Elixinol Global to Present at Upcoming U.S. Investor Conferences Elixinol Global Limited (EXL or the Company) (ASX:EXL; OTCQX:ELLXF), a global company operating in the industrial hemp, dietary supplements and emerging medicinal cannabis sectors, is attending the follow
Slide 2: EXL's businesses include Elixinol, Hemp Foods Australia, Nunyara
food and wellness products, as well as cultivation and manufacture of medicinal cannabis products. EXL’s businesses include: ● Elixinol LLC (“Elixinol”), founded in 2014, is a manufacturer and global distributor of hemp dietary supplement and skincare products, with operations based out of Colorado,
Slide 3: Investor update: March / April 2019
Investor update: March / April 2019 ASX: EXL | OTCQX: ELLXF | www.elixinolglobal.com
Slide 4: Disclaimer
Disclaimer This presentation contains summary information about Elixinol Global Limited (EXL) and its subsidiaries and their activities. The information in this presentation does not purport to be complete. It should be read in conjunction with EXL’s other periodic and continuous disclosure announce
Slide 5: Agenda
Agenda Cannabis definition 4 Who we are 5 Key highlights for financial results FY2018 8 Business overview 10 Financial results FY2018 19 Outlook 23 Q+A 26 Appendix 27 www.elixinolglobal.com
Slide 6: Cannabis definition
Cannabis Who we Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results 4 EXL | FY2018 Results Presentation
Slide 7: Who we are
Cannabis Who we Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Who we are Benefiting health and wellness in communities around the world Elixinol Global (herein referred to as EXL) owns numerous consumer brands in multiple cannabis verticals, including CBD- ba
Slide 8: Why we're different
Cannabis Who we Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Why we’re different We believe our products represent the highest quality in the market • Widely recognized global brand with industry leading products delivered in multiple form factors • Highly d
Slide 9: Capital structure, board and key management
Cannabis Who we Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Capital structure Key Board and market statistics* management team Key market 1 Key statistics market statistics* Andrew Duff | Non-Executive Chairman Experienced ASX listed company director. Ex CF
Slide 10: Key highlights for FY2018
Key highlights for FY2018 www.elixinolglobal.com
Slide 11: Key highlights for FY2018 (December 31 year end)
Cannabis Who we Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Key highlights for FY2018 (December 31 year end) 1 Revenue FY2018 $37.1m vs FY2017 $16.8m, 121% growth Group results Underlying EBITDA FY2018 $0.7m vs FY2017 breakeven FY2018 Underlying NPAT FY2018
Slide 12: Business overview
Business overview www.elixinolglobal.com
Slide 13: Diversified portfolio
Cannabis Who we Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Diversified portfolio FY2018 revenue by business unit Consumer Products Pharmaceutical Dietary Supplements Hemp Foods Medicinal Cannabis Revenue $32.5m (87%)* Revenue $4.9m (13%)* Seeking licence a
Slide 14: Strong growth trajectory across key metrics
Cannabis Who we Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Strong growth trajectory across key metrics EXL has maintained a strong growth trajectory Revenue Underlying EBITDA A$ million, 31 December year end A$ million, 31 December year end $50 $40 37.1 12
Slide 15: Revenue growth by Consumer Products segment
Cannabis Who we Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Revenue growth by Consumer Products segment Growth across all revenue segments with a clear strategy to drive higher margin products Elixinol USA Hemp Foods Australia A$ million, 31 December year e
Slide 16: Elixinol Global key growth initiatives
Cannabis Who we Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Elixinol Global key growth initiatives Continued disciplined approach to drive future revenue growth Investment in farming and production capabilities to facilitate future growth Key sales hire
Slide 17: Elixinol Global, international footprint
Cannabis Who we Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Elixinol Global, international footprint An established platform that can be leveraged for consumer products Global platform for growth • Avenues to market established across • Operations (pins) in
Slide 18: Growth Drivers: Elixinol
Cannabis Who we Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Growth Drivers: Elixinol Firmly positioned to drive revenue growth and take CBD market share • Doubling production capacity in the USA with new 12,000 sq. ft. square foot Colorado facility (to be c
Slide 19: Growth Drivers: Hemp Foods Australia
Cannabis Who we Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Growth Drivers: Hemp Foods Australia Leveraging industry leading position in Australia to further accelerate growth • Solidify #1 market position in Australia for hemp food branded • Launched new S
Slide 20: Growth Drivers: Nunyara Pharma (Australia)
Cannabis Who we Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Growth Drivers: Nunyara Pharma (Australia) Leveraging US cannabinoid production and formulation expertise for Medical Cannabis Subject to ODC licenses and planning approvals: • The planned facility
Slide 21: FY2018 financial results
FY2018 financial results www.elixinolglobal.com
Slide 22: Financial summary
Cannabis Who we Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Financial summary Building scale to support expected future growth ($m) FY2018 FY2017 ($m) FY2018 FY2017 Commentary ($m) Revenue FY2018 37.1 FY2017 16.8 Revenue Cost of goods sold (17.2) (6.3) • gr
Slide 23: Cash flow
Cannabis Who we Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Cash flow Re-investment to facilitate expected future growth ($m) FY2018 FY2017 Commentary Operating activities (5.7) (1.2) Operating cash flow Investing activities (8.5) (0.5) • working capital ex
Slide 24: Strong financial position
Cannabis Who we Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Strong financial position Strong cash position and minimal debt ($m) 31 Dec 2018 31 Dec 2017 Commentary Current assets Strong cash position Cash and cash equivalents 42.9 18.8 • strong net cash pos
Slide 25: Outlook
Outlook www.elixinolglobal.com
Slide 26: Outlook
Cannabis Who we Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Outlook Paul Benhaim, CEO Elixinol Global stated: “ We are very pleased with our revenue growth of 121% for FY2018 across our businesses globally. Meetings with large national outlets have indicate
Slide 27: Strategic outlook: delivering on our corporate strategy
Cannabis Who we Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Strategic outlook: delivering on our corporate strategy Capturing substantial global growth opportunity in hemp-CBD and medicinal cannabis FY2021 • Global top 3 leadership FY2020 position in CBD FY
Slide 28: Q&A
Q&A www.elixinolglobal.com
Slide 29: Appendix
Appendix www.elixinolglobal.com
Slide 30: Reconciliation to FY2018 underlying EBITDA and NPAT
Cannabis Who we Key Business Financial Outlook Q&A Appendix Definition are Highlights Overview Results Reconciliation to FY2018 underlying EBITDA and NPAT ($m) FY2018 Statutory NPAT (0.9) Tax expense 0.4 Depreciation & amortization 0.8 Interest income/finance costs (0.4) Statutory EBITDA (0.1) Share
Slide 31: For more information
For more information: Investor relations and media please contact: Australia United States of America Glen Zurcher Cody Slach Account Director, IR Department Managing Director, Liolios Group Inc [email protected] | +61 420 249 299 [email protected] | +1 949 574 3860 www.elixinolglobal.com
Elixinol Global — 31st Annual ROTH Capital Partners Conference 2019 on 6ix